We are pleased to announce the launch of two new anti-S100A4 antibodies from PPMX.
The reactivity of these antibodies has been validated in sandwich ELISA. When used as a matched antibody pair, they enable the highly sensitive and accurate detection of trace levels of S100A4 in serum samples.
S100A4 has been increasingly investigated as a biomarker for disease progression and therapeutic response in a variety of disease areas. As interest in S100A4 biology and its clinical relevance continues to grow, there is an increasing need for reliable tools for its detection and quantification.
These newly launched antibodies are expected to facilitate S100A4 research by providing a reliable option for sensitive biomarker detection. We hope they will contribute to ongoing basic, translational, and clinical research conducted by investigators worldwide.
|